COSTA MESA, Calif.--(BUSINESS WIRE)--Cerebain Biotech Corp. (OTC: CBBT), today announced that it has entered into a Letter of Intent to purchase the assets of PKG, Inc. (PKG).

PKG, Inc. was established in 1989 and is a privately held corporation based out of Meridian, ID. PKG, Inc. is a leading contract design, developer, and manufacturing company for system-level devices with expertise in human-machine interfaces focusing on healthcare, industrial, aerospace and government products. For the past 30 years PKG has been a major contributor in designing and manufacturing numerous and diverse devices for Fortune 500 companies, mid-size organizations, and start-up businesses. With complete in-house vertical integration, PKG provides its customers with all of their product development needs from R&D, design & development, verification & validation, final product manufacturing, product testing, service and warranty and end of life product support and transitioning.

About Cerebain Biotech Corp.

Cerebain Biotech Corp. (OTC: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.